U.S. market Closed. Opens in 11 hours 17 minutes

IMGN | ImmunoGen, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for IMGN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is passable.

Valuation (10%)

Company Industry
P/E Ratio (TTM) -122.93 -16.22
PEG Ratio (TTM) -1.23 -1.41
P/S Ratio (TTM) 30.34 48.82
P/B Ratio (TTM) 16.00 21.13
P/FCF Ratio (TTM) -43.68 9.38
Price to 5YR AVG Earnings Ratio -37.55 -0.21
Price to 5YR AVG FCF Ratio -54.21 -7.10

Profitability (25%)

Company Industry
ROA (TTM) -8.89% -3.10%
ROE (TTM) -21.97% 24.21%
Net Profit Margin (TTM) -25.41% -1,069.78%
ROIC 5YR AVG 96.25% 16.50%

Growth (55%)

4QTR AVG 3YR AVG 5YR AVG
EPS 216.82% 20.96% -13.74%
Revenue 73.01% 20.10% 8.51%
Net Income 242.26% -0.73% -47.30%
Cash Flow 24.35% -739.65% -482.25%

Health (58%)

Company Industry
Current Ratio (TTM) 5.47 5.75
Quick Ratio (TTM) 5.47 5.47
D/E Ratio (TTM) 0.08 -15.13
Interest Coverage (TTM) -20.26 3.59
Piotroski F-Score 1 5
Altman Z-Score 18.14 13.47
LTL to 5YR AVG FCF -0.07 0.20
Shares Outstanding Growth 5YR AVG 22.26% 118.86%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙